Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
X4 Pharmaceuticals ( (XFOR) ) has issued an announcement.
X4 Pharmaceuticals announced a strategic restructuring on February 6, 2025, involving a workforce reduction of approximately 30%, the closure of its Vienna facility, and a focus on advancing mavorixafor for chronic neutropenia. This restructuring aims to decrease annual spending by $30-35 million and extend the company’s cash runway into the first half of 2026, by streamlining operations to enhance the global market opportunity for mavorixafor.
More about X4 Pharmaceuticals
X4 Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases of the immune system. The company leverages expertise in CXCR4 and immune system biology and has developed mavorixafor, an orally available CXCR4 antagonist marketed in the U.S. as XOLREMDI for the treatment of WHIM syndrome, a rare immunodeficiency.
YTD Price Performance: -17.87%
Average Trading Volume: 5,523,160
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $105.2M
For an in-depth examination of XFOR stock, go to TipRanks’ Stock Analysis page.
